US 12,030,927 B2
Antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2
Juthathip Mongkolsapaya, Oxford (GB); and Gavin Screaton, Oxford (GB)
Assigned to RQ Biotechnology Limited, London (GB)
Filed by RQ BIOTECHNOLOGY LIMITED, London (GB)
Filed on Feb. 17, 2023, as Appl. No. 18/171,216.
Claims priority of application No. 2202232 (GB), filed on Feb. 18, 2022; application No. 2203423 (GB), filed on Mar. 11, 2022; application No. 2206777 (GB), filed on May 9, 2022; application No. 2212470 (GB), filed on Aug. 26, 2022; application No. 2214036 (GB), filed on Sep. 26, 2022; application No. 2215418 (GB), filed on Oct. 18, 2022; and application No. 2301959 (GB), filed on Feb. 10, 2023.
Prior Publication US 2023/0265170 A1, Aug. 24, 2023
Int. Cl. C07K 16/10 (2006.01); A61P 31/14 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/10 (2013.01) [A61P 31/14 (2018.01); A61K 2039/505 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] 26 Claims
 
1. An antibody capable of binding to the spike protein of coronavirus SARS-CoV-2, wherein the antibody comprises: a CDRH1 comprising the amino acid sequence of SEQ ID NO: 955, a CDRH2 comprising the amino acid sequence of SEQ ID NO: 956, a CDRH3 comprising the amino acid sequence of SEQ ID NO: 957, a CDRL1 comprising the amino acid sequence of SEQ ID NO: 958, a CDRL2 comprising the amino acid sequence EVS, and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 960, wherein the antibody comprises a M252Y/S254T/T256E(YTE) mutation according to IMGT numbering.